Newron Pharmaceuticals Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	15.84	-16.22	-17.49	-14.9	-21	Upgrade
Depreciation & Amortization	0.19	0.2	0.2	0.21	0.22	Upgrade
Stock-Based Compensation	0.26	0.2	0.48	0.76	1.46	Upgrade
Other Operating Activities	3.85	4.17	3.83	2.75	0.01	Upgrade
Change in Accounts Receivable	-44.22	-1.31	-0.88	1.75	1.23	Upgrade
Change in Accounts Payable	2.63	0.58	0.58	-3.95	0.56	Upgrade
Change in Other Net Operating Assets	3.84	2.24	2.19	1.93	1.94	Upgrade
Operating Cash Flow	-17.61	-10.14	-11.09	-11.45	-15.59	Upgrade
Capital Expenditures	-0.01	-0.01	-0.02	-0.02	-0.03	Upgrade
Sale (Purchase) of Intangibles	-	-	-	-	-0	Upgrade
Investment in Securities	3.17	3.26	-0.3	8.44	-0.58	Upgrade
Investing Cash Flow	3.16	3.25	-0.32	8.42	-0.62	Upgrade
Long-Term Debt Issued	-	-	-	15	7.5	Upgrade
Long-Term Debt Repaid	-0.19	-0.19	-0.19	-0.17	-0.14	Upgrade
Net Debt Issued (Repaid)	-0.19	-0.19	-0.19	14.83	7.37	Upgrade
Issuance of Common Stock	15.41	-	-	-	-	Upgrade
Other Financing Activities	-0.17	-	-	-	-	Upgrade
Financing Cash Flow	15.05	-0.19	-0.19	14.83	7.37	Upgrade
Net Cash Flow	0.6	-7.09	-11.6	11.81	-8.84	Upgrade
Free Cash Flow	-17.63	-10.15	-11.11	-11.47	-15.62	Upgrade
Free Cash Flow Margin	-34.30%	-112.08%	-182.31%	-198.98%	-297.11%	Upgrade
Free Cash Flow Per Share	-0.86	-0.57	-0.62	-0.64	-0.88	Upgrade
Cash Interest Paid	1.9	1.2	1.23	0.87	0.61	Upgrade
Levered Free Cash Flow	-26.67	-9.22	-9.64	-10.04	-10.14	Upgrade
Unlevered Free Cash Flow	-23.95	-6.61	-7.17	-8.22	-8.74	Upgrade
Change in Net Working Capital	40.75	-0.27	-0.48	1.45	-0.91	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.